Index to this page

Gene Therapy I

Many human diseases are caused by defective genes.

A few common examples:
DiseaseGenetic defect
hemophilia Aabsence of clotting factor VIII
cystic fibrosisdefective chloride channel protein
muscular dystrophydefective muscle protein (dystrophin)
sickle-cell diseasedefective beta globin
hemophilia Babsence of clotting factor IX
severe combined immunodeficiency (SCID)any one of several genes fail to make a protein essential for T and B cell function

All of these diseases are caused by a defect at a single gene locus. (The inheritance is recessive so both the maternal and paternal copies of the gene must be defective.) Is there any hope of introducing functioning genes into these patients to correct their disorder? Probably.

Other diseases also have a genetic basis, but it appears that several genes must act in concert to produce the disease phenotype. The prospects of gene therapy in these cases seems far more remote.

Case study: severe combined immunodeficiency (SCID)

SCID is a disease in which the patient has neither

It is a disease of young children because, until recently, the absence of an immune system left them prey to infections that ultimately killed them.

About 25% of the cases of SCID are the result of the child being homozygous for a defective gene encoding the enzyme adenosine deaminase (ADA). The normal catabolism of purines is deficient, and this is particularly toxic for T cells and B cells.

Treatment Options:

Gene Therapy: requirements

All these requirements seem to have been met for SCID therapy using a retrovirus as the gene vector. Retroviruses have several advantages for introducing genes into human cells. Packaging cells are treated so they express: Treated with these two genomes, the packaging cell produces a crop of retroviruses with:

Once the virus has infected the target cells, this RNA is reverse transcribed into DNA and inserted into the chromosomal DNA of the host.

What to use for target cells?

T cells

The first attempts at gene therapy for SCID children (in 1990), used their own T cells (produced following ADA-PEG therapy) as the target cells.

The T cells were: The children developed improved immune function but:

Stem cells

Blood ("hematopoietic") stem cells:
Discussion of blood stem cells

In June of 2002, a team of Italian and Israeli doctors reported on two young SCID patients that were treated with their own blood stem cells that had been transformed in vitro with a retroviral vector carrying the ADA gene. After a year, both children had fully-functioning immune systems (T, B, and NK cells) and were able to live normal lives without any need for treatment with ADA-PEG or immune globulin (IG). The doctors attribute their success to first destroying some of the bone marrow cells of their patients to "make room" for the transformed cells.

Nine years later (August 2011) these two patients are still thriving and have been joined by 28 other successfully-treated children most of whom no longer need to take ADA-PEG.

Gene Therapy for X-linked SCID

Gene therapy has also succeeded for 20 baby boys who suffered from another form of severe combined immunodeficiency called X-linked SCID because it is caused by a mutated X-linked gene encoding a subunit — called γc (gamma-c) — of the receptor for several interleukins, including interleukin-7 (IL-7).

IL-7 is essential for converting blood stem cells into the progenitors of T cells. [View]. Boys with X-linked SCID can make normal B cells, but because B cells need T-helper cells to function, these boys could make neither cell-mediated nor antibody-mediated immune responses and had to live in a sterile bubble before their treatment.

Their doctors The results: Now after as long as 11 years, 19 of these boys
* Five of the little boys developed leukemia (one has died):

Gene Therapy for β-thalassemia

β-thalassemia is an inherited disease. The most severe cases result from mutations in both copies of the gene encoding the beta chain of hemoglobin. Many causative mutations have been identified, and most lead to a failure to make any beta chains. The resulting hemoglobin functions poorly and the person requires frequent blood transfusions.

In the 16 September 2010 issue of Nature, Cavazzana-Calvo (and many colleagues) report a single case of successful gene therapy for this disorder. Their patient was an 18-year old male.

Their procedure:

The result: Almost three years later, the patient is well and no longer requires periodic blood transfusions. One-third of his hemoglobin is now manufactured by the red-cell precursors descended from the gene-altered stem cells.

And using a similar procedure,

Adenovirus Vectors

Adenoviruses are human pathogens responsible for some cases of the human "cold". Modified versions of two strains are currently being used as vectors in gene therapy trials.

Advantages: Disadvantages:

Link to discussions of other approaches to gene therapy that are being tried.
Welcome&Next Search

2 March 2017